GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK233705 12.5mcgDrug: GSK233705 25mcgDrug: GSK233705 50mcgDrug: GSK233705 100mcgDrug: GSK233705 200mcgDrug: Placebo
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 576
- Registration Number
- NCT00676052
- Locations
- 🇬🇧
GSK Investigational Site, Norwich, United Kingdom
Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: GSK Biologicals' meningococcal vaccine GSK134612Biological: Menjugate
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 414
- Registration Number
- NCT00674583
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00675090
- Locations
- 🇬🇧
GSK Investigational Site, Southall, United Kingdom
GW823296 Repeat Dose Study In Healthy Male And Female Subjects
- Conditions
- Healthy Subjects
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00675116
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00675064
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT00674635
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhzhya, Ukraine
A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00671424
- Locations
- 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00671216
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00666081
FTIH Study With GSK958108
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00664365
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom